Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium

References

• Intermutualistic Agency Atlas. [cited Sept 2021]. Available from: http://atlas.aim-ima.be/base-de-donnees;
   Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045.
   Google Scholar
• Varghese RT, Jialal I, Doerr C. Diabetic nephropathy (nursing). Treasure Island (FL): StatPearls; 2021.
   Google Scholar
• Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–308.
   Google Scholar
• Pagels AA, Soderkvist BK, Medin C, et al. Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment. Health Qual Life Outcomes. 2012;10:71.
   Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension. 2003;42(5):1050–1065.
   Google Scholar
• Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17(7):2034–2047.
   Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
   Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869.
   Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860.
   Google Scholar
• European Medicines Agency Invokana - summary of opinion (post authorisation). 2020. Available from: https://www.ema.europa.eu/en/documents/smop/chmp-postauthorisation-summary-positive-opinion-invokanaii-46_en.pdf.
   Google Scholar
• Dratwa M, Bogaert AM, Bouman K, et al. The economic burden of dialysis patients in Belgium: a comparison between haemo and peritoneal dialysis. 2013;15:208–222.
   Google Scholar
• Farahani P. A perspective on principles of comparative cost-effectiveness studies for pharmacotherapy of chronic diseases. Clin Diabetes. 2012;2(30):54.
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation (handbooks in health economic evaluation). 1st ed. Oxford: Oxford University Press; 2006.
   Google Scholar
• Willis M, Asseburg C, Slee A, et al. Development and internal validation of a discrete event simulation model of diabetic kidney disease using CREDENCE trial data. Diabetes Ther. 2020;11(11):2657–2676.
   Google Scholar
• Karnon J, Stahl J, Brennan A, et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM modeling good research practices task force-4. Med Decis Making. 2012;32(5):701–711.
   Google Scholar
• Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019;140(9):739–750.
   Google Scholar
• Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(21):2099.
   Google Scholar
• Vemer P, Corro Ramos I, van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349–361.
   Google Scholar
• Belgian list price. [cited March 18 2021]. Available from: https://www.bcfi.be/nl/chapters/6?frag=20701&view=pvt&vmp_group=33175
   Google Scholar
• Tattersall J, Dekker F, Heimburger O, et al. When to start dialysis: updated guidance following publication of the initiating dialysis early and late (IDEAL) study. Nephrol Dial Transplant. 2011;26(7):2082–2086.
   Google Scholar
• Vernooij RWM, Law W, Peters SAE, et al. The probability of receiving a kidney transplantation in end-stage kidney disease patients who are treated with haemodiafiltration or haemodialysis: a pooled individual participant data from four randomised controlled trials. BMC Nephrol. 2021;22(1):70.
   Google Scholar
• Willis M, Nilsson A, Kellerborg K, et al. Cost-effectiveness of canagliflozin added to standard of care for treating diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM) in England: estimates using the CREDEM-DKD model. Diabetes Ther. 2021;12(1):313–328.
   Google Scholar
• Neuen BL, Ohkuma T, Neal B, et al. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program. J Am Soc Nephrol. 2019;30(11):2229–2242.
   Google Scholar
• Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
   Google Scholar
• Willis M, Durkin M, Neslusan C, et al. Estimated renal and cardiovacular outcomes and cost offsets in patients with type 2 diabetes (T2D) and diabetic nephropathy (DKD) treated with canagliflozin, in Poster Presentation at ISPOR Virtual Meeting 2020. 2020.
   Google Scholar
• Sugrue DM, Ward T, Rai S, et al. Economic modelling of chronic kidney disease: a systematic literature review to inform conceptual model design. Pharmacoeconomics. 2019;37(12):1451–1468.
   Google Scholar
• Personal communications in May 2021 with Klinisch Labo Rigo, Bosdel 89, 3600 Genk.
   Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22(4):340–349.
   Google Scholar
• Jommi C, Armeni P, Battista M, et al. The cost of patients with chronic kidney failure before dialysis: results from the IRIDE observational study. Pharmacoecon Open. 2018;2(4):459–467.
   Google Scholar
• Jesky MD, Dutton M, Dasgupta I, et al. Health-related quality of life impacts mortality but not progression to end-stage renal disease in pre-dialysis chronic kidney disease: a prospective observational study. PLoS One. 2016;11(11):e0165675.
   Google Scholar
• Lee AJ, Morgan CL, Conway P, et al. Characterisation and comparison of health-related quality of life for patients with renal failure. Curr Med Res Opin. 2005;21(11):1777–1783.
   Google Scholar
• Van Biesen W, Peeters P, Vanholder R. Belgium’s mixed private/public health care system and its impact on the cost of end-stage renal disease. Int J Health Care Finance Econ. 2007;7(2–3):133–148.
   Google Scholar
• Caekelbergh K, Lamotte M, Kutikova L, et al. Short and long term costs associated with different cardiovascular events in Belgium. Value Health. 2016;19:A347–A766 .
   Google Scholar
• van Haalen HG, Pompen M, Bergenheim K, et al. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig. 2014;34(2):135–146.
   Google Scholar
• Shingler S, Fordham B, Evans M, et al. Utilities for treatment-related adverse events in type 2 diabetes. J Med Econ. 2015;18(1):45–55.
   Google Scholar
• Roze S, Duteil E, Smith-Palmer J, et al. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands. J Med Econ. 2016;19(8):742–749.
   Google Scholar
• Peasgood T, Brennan A, Mansell P, et al. The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with Type I diabetes. Med Decis Making. 2016;36(8):1020–1033.
   Google Scholar
• Sullivan PW, Ghushchyan VH. EQ-5D scores for diabetes-related comorbidities. Value Health. 2016;19(8):1002–1008.
   Google Scholar